FDA Grants Accelerated Approval for Ojemda (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the“Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news